$Roivant Sciences (ROIV.US)$ extremely undervalued, by at least 60%? Roivant stock was already priced at ~ $7 with a market cap of $5 Billion when it licensed RVT-3101 from Pfizer for $45 million back in Dec, 2022. Now Roivant just pocketed $5 billion from selling it to Roche, so its stock price shall at least raise to $14 to justify the huge gain only from the Roche deal by simple math, that's probably also why its average analyst price target is about $16.

$Roivant Sciences (ROIV.US)$ Why ROIV is up today?
Roivant Announced Warrants Redemption Fair Market Value at$11.35 after hours yesterday. Redemption Fair Market Value (FMV) is the price that a company will pay to holders of outstanding warrants to redeem them. If the FMV is greater than the stock price, then warrant holders will be more likely to exercise their warrants, as they will be able to buy shares of stock at a discount.

$Roivant Sciences (ROIV.US)$ Why ROIV seems to be often very sensitive to Nasdaq fluctuations?
This may be because hedge funds are its major shareholders (~35%) as hedge funds are typically more active traders than other types of investors, and they are more likely to sell their shares when the market is volatile.
Hedge funds are also more likely to sell their shares when the market is volatile. This is because they are more concerned with protecting their profits than with maximizing their retur...

$Roivant Sciences (ROIV.US)$ A biotech/pharma buyout/license deal is more likely to happen when the target company's stock is under pressure as a falling stock price can make the target company more attractive to buyers.
1) a falling stock price can make the target company more affordable for buyers, a major incentive for buyers, especially if they believe that the target company has valuable assets or technology.
2)a falling stock price can make the target company's shareholders more willing to ...

$Roivant Sciences (ROIV.US)$ Which companies have drugs in clinical trials phase 2-3 for treatment of ulcerative colitis (UC) and Crohn's disease (CD) targeting tumor necrosis factor-like ligand 1A (TL1A)? There are only two. One is Prometheus Biosciences, which was acquired by Merck for ~$11 Billion (https://www.merck.com/news/merck-completes-acquisition-of-prometheus-biosciences-inc/) for this specific type of drug in phase 2a for UC just months ago. The other one is Roivant, whose RVT-3101 has...